W e have reported that 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylideine)malononitrile ([F-18]FDDNP) has a high affinity for β-pleated sheet fibrillar neuroaggregates,
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which provide a high binding potential for in vivo imaging visualization of tau and amyloid fibrils. [1] [2] [3] We previously reported unique [F-18] FDDNP-PET patterns in the brains of 5 National Football League (NFL) players with suspected chronic traumatic encephalopathy (CTE). 4 We further characterized and reported the in vivo [F-18] FDDNP patterns and selective topographic distributions of CTE neuropathology in the living brains of 14 retired NFL players and compared the distinctive CTE patterns to those of 28 cognitively intact controls and 24 Alzheimer's disease patients. 1 CTE, like other brain diseases, exhibits selective topographic vulnerability 5 that progresses to involve more regions of the brain in diffuse and global patterns 1 as the Graduated from college (Bachelor of Arts in Economics) before playing in the NFL. 3 .
Began attending law school in 12th NFL year. 4 .
Graduated from law school (Juris Doctorate) 2 yr after retirement from the NFL. 5 .
Practiced law in a law firm, moved to another law firm, became partner. a. Dismissed as partner 3-4 yr later for lack of performance. 6.
Became a sole practitioner, relocated to another state, passed another bar examination. 7 .
Worked in a new law firm, was later dismissed for lack of performance. 8.
Worked in another law firm, was later dismissed, pattern continued. 9.
Stopped practicing law 25 yr after retirement from the NFL. 10.
Socioeconomic status deteriorated progressively, filed for bankruptcy.
Our patient had a 22-yr cumulative lifetime risk exposure to football and manifested a progressive decline in his work status and performance over decades, which eventually resulted in a bankruptcy.
disease advances. The ability to identify CTE inthe brains of living patients is a prerequisite step for complete elucidation of CTE pathogenesis and development of cures. 6 In pursuit of this prerequisite step, we present an autopsy confirmation in a retired NFL player with CTE, who had an antemortem [F-18]FDDNP-PET scan with a distinctive CTE pattern.
METHODS

Medical History
Our patient's medical, football, and work histories were collated and reviewed. A postmortem surrogate interview of his wife and next-of-kin was performed. He was a 59-yr-old African-American man at the time of [F-18] FDDNP-PET scanning. The magnetic resonance imaging (MRI) scan at the time of the [F-18]FDDNP-PET imaging showed mild, global brain atrophy with enlarged ventricles, moderate bilateral hippocampal atrophy, and diffuse white matter hyperintensities.
Two years after his [F-18]FDDNP-PET scan, at age 61, his wife noticed progressive motor deficits, including inability to button his shirts, zip his pants or tie his shoes, and eventually feed himself. She reported that he developed muscle twitching (without cramps) in his arms and decreased muscle mass in his shoulders and arms without any sensory changes. Clinical examinations about 6 to 8 mo after the onset of his motor symptoms revealed decreased muscle bulk in the bilateral upper extremities with normal tone, atrophy of the intrinsic hand muscles, and weakness of the biceps bilaterally. Electromyography determinations of selected bilateral upper and lower extremity, and cervical-lumbar paraspinal muscles revealed active and chronic denervation changes in nearly all muscles tested. Approximately 17 mo prior to death, he was diagnosed with Motor Neuron Disease/Amyotrophic Lateral Sclerosis in addition to his pre-existing clinical and presumptive diagnosis of CTE.
During the final months of his life, our patient was admitted to a nursing home for dehydration, failure to thrive, progressive dysphagia, incontinence, progressive neck and limb weakness, and slurred speech. He eventually died at the age of 63. Full autopsy was not performed, but his brain and spinal cord were harvested for neuropathological examination.
Neuropsychological evaluation of the patient was performed at the time of [F-18]FDDNP-PET scanning. 7, 8 Antemortem [F-18]FDDNP-PET Brain Scan [F-18] FDDNP-PET imaging of the brain was performed approximately 52 mo prior to death. The study was performed under standard ethics guidelines as have been previously reported. 4 [F-18]FDDNP radiochemistry has been previously described and reported. 1, 4, 9, 10 PET scan determinations and quantification of the [F-18]FDDNP binding data have been previously reported. 1, 4, [11] [12] [13] The distribution volume ratio (DVR) parametric images were generated and analyzed with the use of regions of interest (ROIs) drawn bilaterally on the co-registered MRI scans for a number of cortical, limbic, and subcortical areas. MRI scans were also performed for the purpose of anatomical reference to aid the analysis of PET data as described previously.
11
Postmortem Autopsy Determination
Upon the subject's death, the next-of-kin contacted the pathologist (BO) for donation of the patient's brain. An informed consent form was signed for brain examination and to obtain the medical records for review. The dura mater, brain, pituitary gland, and spinal cord were harvested within 48 h of death, and fixed in 10% buffered formaldehyde for 3 wk. The sections were then washed for 24 h in a water bath, measured, grossed, and dissected. Began losing personal objects.
4.
Became short-tempered, often felt panicked, was less organized.
5.
Became fixated on ideas and less interested in activities he previously enjoyed. 6.
Transformed from a kind, mild-mannered "gentle giant" to a very agitated person. a. Exhibited angry outbursts that were out of character. 7.
Behaved inappropriately as if "his filter was gone. " 8.
Evaluated by a psychiatrist, diagnosed with depression, and "probable CTE. "
Our patient exhibited negative family history for dementia or major psychiatric illness. According to his wife and next-of-kin, he exhibited progressive cognitive decline for many years after retirement from the NFL. Hamilton Depression Rating (17-item) 8
Hamilton Anxiety Scale 13
Comprehensive psychopathological cognitive assessment of the patient at the time of the [F-18]FDDNP-PET scan for the in vivo detection of neuropathological substrates in the brain. Our subject was diagnosed with mild cognitive impairment with deficits in multiple cognitive domains, eg, memory, attention, information processing speed, language, and executive functioning.
MRI/PET maps and regions of interest were used for the determination of DVR values. Similar regions of interest matching the MRI/PET maps were targeted in the neuropathological tissue sectioning and microscopic examination. A battery of histochemical and immunohistochemical stains was performed on each submitted section in addition to routine hematoxylin and eosin (H/E). The brain slides were independently examined microscopically by 2 neuropathologists (BO and JL) and 1 forensic pathologist (JH). All 3 pathologists were in agreement with the findings and diagnoses. Histomorphological, proteinopathic, and neuroinflammatory changes were noted on all stained slides. The No fibrocystic membrane or xanthochromia in dura mater. 2.
Mild, diffuse, symmetrical cortical atrophy, cerebral and cerebellar hemispheres.
3.
No remote contusional necrosis of brain. 4.
Moderate, symmetrical, bilateral dilatation of all ventricles. 5.
Cavum septum pellucidum, present, without fenestrations of the septum pellucidum. 6.
Mild, bilateral, symmetrical atrophy of the cornu ammonis. 7.
No segmental necrosis or atrophy of spinal medulla. 8.
Multifocal sparse perivascular hemosiderin-laden histiocytes, Virchow Robin spaces. 9.
Diffuse, mild, neuronal loss, neocortex, subcortical nuclei, and cerebellar cortex. 10.
Severe loss of pyramidal neurons, Sommer's sector.
11.
No granulovacuolar neuronal degeneration or Hirano bodies in stratum pyramidalis. 12.
No necrosis or degeneration of the anterior, lateral, and posterior spinal funiculi. 13.
Mild neuronal loss, cervical, thoracic, and lumbar spinal medulla.
Gross and histologic (hematoxylin and eosin) examination of the brain and spinal cord revealed nonspecific findings without any focal parenchymal contusional necrosis.
distribution and density of the proteinopathic changes were classified into 4 semiquantitative categories adapted from the neuritic plaque density assessment of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD). 14 The 4 adapted categories are as follows: none (0), sparse (1), moderate (2), and frequent (3). The same categorization was applied to pathological changes seen on the cluster of differentiation 68 (CD-68), glial fibrillary acidic protein (GFAP), and luxol fast blue-cresyl violet (LFB-CV) stains.
Statistical Analysis
Topographic distribution of observed proteinopathies in the brain was compared to the documented topographic distribution of the [F-18]FDDNP-PET brain imaging findings. Correlation analysis was performed using Spearman rank-order correlation. Correlation between [F-18]FDDNP-PET DVRs and tau, amyloid, or TDP-43 deposit densities, was obtained and was corrected for multiple comparisons using the Benjamini-Hochberg method 15 and controlled the false discovery rate (FDR) to be 10%. Statistical significance was set at P < .05 (2-sided). Statistical analysis was performed using the SAS 9.4 for Windows (SAS Institute Inc, Cary, North Carolina).
RESULTS
Summaries of our patient's football, work, and medical histories are presented in Tables 1-3 .
Brain and Spinal Gross and Histologic Findings
The gross and H/E brain and spinal findings are summarized in Table 4 . The LFB-CV stains revealed diffuse, global, mild loss of myelin in the cortical and subcortical white matter including the corpus callosum ( Table 5 ). The Bielschowsky silver stains highlighted the tau and amyloid neuropathological substrates described below.
The tau immunostains revealed sparse to frequent neuronal and glial fibrillary tangles and inclusions, neuropil threads and dot-like lesions, and ghost neurofibrillary tangles, which were differentially and topographically distributed in both the brain and spinal cord ( Table 5 ). All these tau neuropathological substrates, in both the gray and white matter, were included in the semiquantitative evaluation of topographic densities, and were not limited to neuronal neurofibrillary tangles. In the spinal cord, the neurons, glia, and neuropil of both the central gray matter and the anterior, lateral, and posterior funiculi were involved by tau neuropathological substrates. The following diagnostic CTE criteria were noted: residual density accentuations of tauopathy in the superficial cortical laminae, in the depths of the sulci, in perivascular regions, and in the subcortical parasagittal and periventricular nuclei, as well as irregular neocortical distributions of tau neuropathological substrates (skip-phenomenon), whereby adjacent regions of the neocortex were skipped by tau substrates. 16, 17 The parasagittal and paraventricular densityaccentuations of tau substrates exhibited a caudal-rostral gradient with highest densities seen in the regions of the brain surrounding the third ventricle and cerebral aqueduct of Sylvius including the periaqueductal and tegmental nuclei of the midbrain and rostral pons, and the locus ceruleus, the hypothalamus, subthalamic nucleus, periventricular posterior thalamus and pulvinar, and the globus pallidus. 16, 17 These subcortical regions, similar to the neocortex, exhibited the skip-phenomenon. These parasagittal and periventricular subcortical regions, with less volume and less surface area when compared to the global neocortex, appeared to show more frequent densities of tau neuropathological substrates per unit surface area and volume, with prominent extra-neuronal tau substrates, in agreement with [F-18]FDDNP-PET findings (Figures 1 and 2 ; Table 5 ). Thorn-shaped astrocytes and features of primary age-related tauopathy or age-related tau astrogliopathy were absent. 18, 19 The beta-A4 amyloid immunostains revealed diffuse and neuritic amyloid plaques that exhibited differential topographic distribution as shown in Table 5 . There was no cerebral amyloid angiopathy in the brain or spinal cord. The amygdala, cerebellum, and spinal cord did not show any diffuse or neuritic amyloid plaques. The brainstem showed none to sparse diffuse and neuritic amyloid plaques. The TDP-43 immunostains revealed inclusions in neurons and glia, and neuropil threads in selective regions of the brain and spinal medulla ( Table 5 ). The alpha-synuclein, ubiquitin, and FUS protein immunostains did not reveal any neuronal or glial inclusions. The CD-68 immunostains showed diffuse, global neuropil histiocytes and activated microglia accentuated perivascularly and in the Virchow Robin spaces. The GFAP immunostains exhibited a similar topographic distribution with diffuse, global isomorphic fibrillary astrogliosis ( Table 5 ).
The regions of the brain with the highest densities of tau pathology showed larger numbers of ghost tangles. Every region of the brain that exhibited amyloid pathology also exhibited the presence of tau pathology in higher densities; however, not every region of the brain that exhibited tau pathology, exhibited corresponding amyloid pathology. The parasagittal and paraventricular subcortical regions showed higher predominance of tau pathology compared to amyloid pathology. Brain ROIs with the highest densities of tau pathology also generally showed TDP-43 pathology deposition, typically subcortical structures (Table 5) . There was no amyloid or tau pathology in the cerebellum.
The clinical and pathological findings, in this case, were consistent with a primary diagnosis of chronic traumatic myeloencephalopathy (CTME), as has been previously described. 16, 17, [20] [21] [22] [23] [24] Figure 3 illustrates the pertinent neuropathological findings.
Comparison of Postmortem Neuropathological Findings with Antemortem [F-18]FDDNP-PET Imaging Results
Neuropathological findings showed indicators of the differential neocortical densities and distributions of tau neuropathological substrates identified by [F-18]FDDNP-PET brain imaging, which showed higher neocortical DVR values for the frontal and temporal cortex, lower DVR values for the parietal cortex, and lowest DVR values for the occipital cortex, in an anteroposterior gradient (Figure 1) . 1 [F-18]FDDNP-PET identified tau pathology in the regions of the brain confirmed by tissue analysis to show tau pathology, and also amyloid pathology in some instances; and identified regions of the brain with only tau pathology or predominant tau pathology such as the midbrain and amygdala.
Correlation analysis was performed to investigate whether the in vivo regional [F-18] FDDNP binding level agreed with the density of tau pathology based on autopsy findings. Spearman rank-order correlation coefficient (r s ) was calculated for the regional [F-18]FDDNP DVRs (Figure 1 ) and the density of tau pathology, as well as for amyloid and TDP-43 substrates (Table 5) . Our results showed that the tau regional findings and densities obtained from antemortem [F-18]FDDNP-PET imaging and postmortem autopsy were highly correlated (r s = 0.592, P = .0202). However, no statistical correlation was found with the presence of amyloid deposition (r s = −0.481; P = .0695) or of TDP-43 (r s = 0.433; P = .1066).
DISCUSSION
Our findings and previously reported research 1,4,25 may confirm that [F-18]FDDNP-PET brain imaging may be selective for predominant tauopathies like CTE and may identify the distinctive selective topographic differential distribution of brain tau pathology. The neuropathological findings, at brain autopsy in this current research, confirmed the in vivo [F-18]FDDNP-PET 'fingerprint' signature of CTE previously reported. 1, 4 CTE has been confirmed to exhibit a distinctive neuropathological signature with differential and selective topographic vulnerability of brain regions, which are temporally progressive 1, 17, [20] [21] [22] 26, 27 eventually recruiting all regions of the brain in advanced CTE. 20, 22 The [F-18]FDDNP-PET brain imaging findings 1, 4 and brain autopsy findings in this current research may further confirm this neuropathological signature.
FIGURE 2. Top panel: immunohistochemistry photomicrographs (×400) of parietal cortex, midbrain, amygdala, and hippocampus show the presence of tau neuropathological deposits in these regions. Bottom panel: representative transaxial (2 sections), sagittal (middle), and coronal sections (right) of [F-18]FDDNP-PET images with high signals in the periventricular subcortical regions, amygdala, and midbrain. Warmer colors (red and yellow) show areas with higher [F-18]FDDNP binding signals.
Selectively vulnerable regions of the brain may differentially manifest the neuropathological substrates of CTE earlier, and in greater quantities per unit volume and surface area, as the disease advances to the late stages when the brain globally manifests these neuropathological substrates. Some of these selectively vulnerable topographic regions of the brain may include, but may not be limited to, the midbrain, pons, limbic structures, parasagittal, and periventricular regions of the brain. 1, 4, 21, 28 These are the sagittal and parasagittal regions of the brain that appear to bear the maximal shearing, angular-rotational acceleration-deceleration forces in traumatic brain injuries and in American football players. [29] [30] [31] This pathology progression involves neuronal circuits that are consistent with the selective and differential clinical symptomatology of CTE, predominantly mood and behavioral symptoms in younger patients, progressing to increasing cognitive deficits, and, eventually, dementia in older patients with advanced stages of CTE 32 as the neocortex becomes globally involved.
Our brain autopsy showed differential distribution of tau and amyloid neuropathological CTE substrates in the bilateral neocortex in a dorsal-ventral gradient, as was observed with [F-18]FDDNP-PET (Figure 1) . 1, 4 A limitation of this work, however, is the 52-mo interval between the [F-18]FDDNP-PET brain imaging and brain autopsy. Since CTE is a progressive disease, further progression of neuropathological substrates should have existed over this period. This is particularly evident in this case, when the subject was diagnosed with motor neuron disease 2 yr after PET scanning, and suffered advancing symptoms until death. In spite of this temporal limitation, remnants of the differential lobar neocortical distribution of tau and amyloid neuropathological substrates were still observed at autopsy. The frontal, temporal, and parietal cortices, at autopsy, revealed uniformly high distribution and densities of neuropathological substrates, while the occipital cortex revealed lower densities (Table 5) . Clinical dementia ratings performed several years prior to death can accurately predict postmortem regional and topographically selective neuropathology. 33, 34 Unfortunately, the spinal cord was not included in the [F-18]FDDNP-PET scanning, since the patient was not manifesting any motor symptoms of CTME at the time of the scanning.
The lack of statistical correlation between our TDP-43 neuropathological findings and [F-18]FDDNP DVRs in this case, as well as the lack of correlation with amyloid deposition, may indicate that the [F-18]FDDNP-PET brain signal, in this case, originated principally in the presence of tau neuroaggregates ( Figure 2 ). As has been previously suggested, the TDP-43 inclusion bodies did not show any amyloid fibrillary structures within them 1, 35 and in vivo [F-18]FDDNP signal was less likely to have significantly originated from these inclusions.
Our prior research 1, 4 and current findings are indicating that [F-18]FDDNP-PET brain imaging may be a useful in vivo radiological tool for the clinical assessment and diagnosis of traumatic encephalopathy syndromes 6 including CTE, CTME, and CTE-PTSD (post-traumatic stress disorder). Further evaluation with clinical trials is warranted. Subconcussion and concussion based CTE may be differentially selective of the regions of the brain that bear the maximal shearing, angular-rotational accelerationdeceleration forces [29] [30] [31] (parasagittal and periventricular regions and nuclei of the brain), progressing in topographic distribution to recruit more neocortical and subcortical regions as the disease advances. This may explain the progressive nature of the clinical symptoms and their correlation with deteriorating neuronal circuits. 1, 4 Further studies are needed to confirm this progressive pathology model in living subjects.
CONCLUSION
In conclusion, our results may suggest that the in vivo identification of CTE substrates in living patients may not only be based on the presence or absence of proteinopathies, but also on the identification of the differential and selective topographic vulnerability unique to CTE, which [F-18] 
